Showing 6,081 results

Filters Content type: News, Editors' picks, About HIV Topic: HIV treatment

Treatment is recommended for all people living with HIV. It involves taking a combination of antiretroviral drugs. This stops the virus from replicating and allows the immune system to strengthen and fight infections.

The biology of HIV transmission

HIV Transmitted Through Heterosexual Sex May Initially Be ‘Fitter,’ but Likely Has No Effect on Prevention and Treatment

Editor's pick
TheBodyPro
26 April 2022
Weight gain & lipodystrophy

Fungai Murau on weight gain in women with HIV – GROWS project Video

April 2022
The search for a cure

Antibody therapy controls HIV for months in new clinical trial

Editor's pick
The Rockerfeller University
22 April 2022
Treatment outcomes & life expectancy

A quarter of 2020 deaths of people with HIV in the UK due to COVID-19

News
21 April 2022
PrEP programmes & uptake

Four in ten PrEP recipients stop taking it within six months, global meta-analysis reveals

News
20 April 2022
Antibody-based treatment

New approach for delivery of anti-HIV antibody therapy shows promise in phase I clinical trial

Editor's pick
EurekAlert
13 April 2022
Improving HIV care

How a national intervention in Botswana improved same-day ART initiation for people newly diagnosed with HIV

News
4 April 2022
The search for an HIV prevention vaccine

Media Headlines Often Suggest That HIV Vaccines and Cures Are Imminent. Not So Fast!

Editor's pick
TheBody
1 April 2022
Injectable & long-acting HIV treatment

Bi-Monthly Injectable HIV-Treatment Drug Cabenuva Listed On Australia's PBS

Editor's pick
Star Observer
1 April 2022
New & experimental HIV treatments

After FDA hold, CytoDyn will appeal for pharma partnerships to save leronlimab

Editor's pick
FierceBiotech
31 March 2022
Injectable & long-acting HIV treatment

US: Cabenuva Approval Expanded to Include Adolescents With HIV

Editor's pick
Monthly Prescribing Reference
31 March 2022
Changing treatment

Outcomes of HIV Virologic Suppression After Switching to Dolutegravir/Lamivudine

Editor's pick
Infectious Disease Advisor
28 March 2022
Changing treatment

17 months average wait to switch from a failing HIV treatment regimen in African countries

News
28 March 2022
Injectable & long-acting HIV treatment

ViiV Healthcare announces label update for its long-acting HIV treatment, Cabenuva (cabotegravir, rilpivirine), to be initiated with or without an oral lead-in period

Editor's pick
ViiV press release
25 March 2022
Improving HIV care

Medical mistrust is linked to discrimination, poor care engagement, and low adherence among Black adults in the US

News
21 March 2022
Economic & social inequality

Income May Be the Biggest Determinant of Whether Women Stay on PrEP

Editor's pick
POZ
18 March 2022
Treatment outcomes & life expectancy

Readmission, Mortality are Post-Discharge Risks for HIV Patients

Editor's pick
Contagion Live
17 March 2022
PEP

Study shows Biktarvy for PEP has fewer side effects and better completion rates

News
16 March 2022
Viral load

Undetectable viral load Illustrated

About HIV
March 2022
Sleep

Fatigue and HIV

About HIV
March 2022
Injectable & long-acting HIV treatment

US: Bottlenecks are slowing switch to GSK's long-acting HIV injectable Cabenuva: clinician

Editor's pick
FiercePharma
9 March 2022
Side effects

Peripheral neuropathy and HIV

About HIV
March 2022
Bone & joint problems

Better adherence to PrEP is associated with more bone loss

News
9 March 2022
Injectable & long-acting HIV treatment

Injectable cabotegravir plus rilpivirine every two months maintains viral suppression for three years, but carries higher risk of treatment failure

News
8 March 2022